Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease

The study proposed here intends to evaluate the safety and efficacy of escalating doses of autologous PMCC-COE-KMA CAR T-cells administered to patients with relapsed/refractory multiple myeloma that expresses the KMA. The PMCC-COE-KMA CAR T-cells will be produced using LV and administered to patients after lymphodepleting conditioning chemotherapy. Considering the poor prognosis of myeloma patients who have relapsed after ≥ 2 lines of therapy, combined with evidence of PMCC-COE-KMA CAR T-cell specificity, as well as the efficacy and manageable toxicity of PMCC-COE-KMA, investigators believe the potential benefits outweigh the risks of this trial.

NCT Number	NCT07541391
Lead Sponsor	Peter MacCallum Cancer Centre, Australia Collaborators: HaemalogiX Ltd
Conditions	Relapsed/Refractory Multiple Myeloma
Enrollment	12 participants
Start Date	2026-05
Primary Completion	2028-09 (estimated)
Study Completion	2030-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-27